Ibogaine - onset.to

October 27, 2026

Weekly Psychedelic Policy Briefing: VA prepares ten treatment sites, DEA reviews five tryptamines, and cannabis hearing stays paused

psychedelicstoday.com · Oct 27, 2026 · Jack Gorsline

Psilocybin Ibogaine Article Clinical +2

October 22, 2026

Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Federal Officials Weigh In on Psychedelic Access

psychedelicalpha.com · Oct 22, 2026

Ibogaine Article Clinical Policy Safety

October 21, 2026

Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try and the Psychedelics Executive Order

psychedelicalpha.com · Oct 21, 2026 · Josh Hardman

Psilocybin Ibogaine Article Industry +2

October 20, 2026

Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing

psychedelicalpha.com · Oct 20, 2026 · Josh Hardman

Psilocybin Ibogaine Podcast Clinical +2

October 16, 2026

Lilly neuroscience president says the company is interested in studying and improving ibogaine through research and development

endpoints.news · Oct 16, 2026

Ibogaine Article Business Industry Research

October 8, 2026

FDA outlines a potential ibogaine trial, while Compass discusses pricing and branding amid psychedelic policy and market developments

psychedelicalpha.com · Oct 8, 2026

Psilocybin Ibogaine Article Business +2

October 7, 2026

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

psychedelicstoday.com · Oct 7, 2026 · Psychedelics Today

Ayahuasca Ibogaine Podcast Education +2

October 5, 2026

Psyence signs a US ibogaine manufacturer, but DEA approvals, import limits, quotas, and clinical filings remain unresolved

behavioralwire.com · Oct 5, 2026 · Editorial Desk

Ibogaine Article Industry Policy Research

FDA Seeks Public Input on Early-Phase Clinical Trial Design and Safety for Ibogaine Drug Products

fda.gov · Oct 5, 2026

Ibogaine Article Clinical Policy Safety

September 21, 2026

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

psychedelicalpha.com · Sep 21, 2026 · Josh Hardman

Ibogaine MDMA Podcast Industry +2

September 16, 2026

Pα+ Psychedelic Bulletin #231 covers Compass’s 52-week psilocybin follow-up, Xylo’s Phase I trial, ibogaine policy, and industry news

psychedelicalpha.com · Sep 16, 2026

Psilocybin Ibogaine Article Industry +2

September 11, 2026

Beyond the Foxhole: How Psychedelic Policy Coalitions Are Expanding From Veterans to First Responders Nationwide

psychedelicstoday.com · Sep 11, 2026 · Logan Davidson

Psilocybin Ibogaine Essay Community +2

The haunting of Shawn Ryan and the possible breakdown of ibogaine's alliance with the Christian right

ecstaticintegration.org · Sep 11, 2026 · Jules Evans

5-MeO-DMT Ibogaine Article Culture +2

September 2, 2026

Psilocybin combined with psychotherapy reduces cocaine use, while animal findings highlight the need for relapse-prevention support

psypost.org · Sep 2, 2026 · Eric W. Dolan

Psilocybin Ibogaine Article Clinical +2

August 25, 2026

University of Miami’s Gift of Its 1994 Ibogaine IND to HHS Advances Open Science While Highlighting Modern Safety and Sourcing Needs

maps.org · Aug 25, 2026

Ibogaine Article Ethics Research Safety

August 22, 2026

Ceremony length tracks drug duration across 11 traditions, linking psychedelic pharmacology with ritual structure and community response

ecstaticintegration.org · Aug 22, 2026 · Jules Evans

LSD Psilocybin Consciousness Culture +6

August 12, 2026

Engineered psychedelic analog in mice retains antidepressant-like and anti-inflammatory effects while avoiding the severe gastrointestinal distress seen with ibogaine

psypost.org · Aug 12, 2026 · Eric W. Dolan

Ibogaine Article Research Safety Therapy

August 10, 2026

Gabon places ibogaine policy within national sovereignty, cultural stewardship, and global demand as international interest in iboga-derived medicine accelerates

psychedelicstoday.com · Aug 10, 2026 · Psychedelics Today

Ibogaine Article Ethics Ethnobotany Policy

August 4, 2026

Puerto Rico establece una política pública para fortalecer la investigación clínica de terapias emergentes sin autorizar su uso rutinario

prfaa.pr.gov · Aug 4, 2026

Psilocybin Ibogaine Article Clinical +2

July 21, 2026

An ibogaine experience shifted a scientist's view of consciousness, addiction, and what psychedelic states may reveal beyond standard neurochemical models

thesporereport.com · Jul 21, 2026 · admin

Ibogaine Article Consciousness Research Therapy

Q3 2026 psychedelic drug development pipeline bullseye charts map clinical-stage programs, company momentum, and the concentration of targets across indications

psychedelicalpha.com · Jul 21, 2026

LSD Psilocybin Clinical Industry +7

July 20, 2026

Ibogain bei Ketamin-Gebrauchsstorung - erster dokumentierter Langzeitfall zeigt anhaltende Abstinenz und klinische Verbesserungen nach 18 Monaten

psychedelia-stiftung.de · Jul 20, 2026

Ibogaine Ketamine Article Clinical +2 DE

July 13, 2026

Gabon places iboga at the center of cultural sovereignty, linking Bwiti tradition, conservation, and control over how a sacred plant enters global psychedelic markets

psychedelicstoday.com · Jul 13, 2026 · Psychedelics Today

Ibogaine Culture Ethnobotany Policy

June 30, 2026

Ibogaine Investigator's Brochure outlines pharmacology, safety profile, and clinical development context for ibogaine in regulated research settings

maps.org · Jun 30, 2026

Ibogaine Clinical Research Safety

MAPS publishes a free open-access ibogaine Investigator's Brochure to support researchers with pharmacology, safety, dosing, and clinical development guidance

maps.org · Jun 30, 2026

Ibogaine Clinical Education Research